A patient with tetanus infection develops symptoms due to a bacterial protein toxin. This toxin is:

Both facilitated diffusion and active transport require carrier proteins to move substances across the plasma membrane, but the mechanisms differ. Facilitated diffusion uses carrier or channel proteins to transport molecules down their concentration gradient without energy expenditure. In contrast, active transport also uses carrier proteins but moves substances against their concentration gradient, requiring energy input, usually from ATP hydrolysis. These proteins provide specificity for particular molecules and enable transport that cannot occur through simple diffusion, ensuring that cells can regulate nutrient uptake, ion balance, and waste removal efficiently.

50/106

A. do not cause many human infections: While some fungi, protozoa, and helminths cause fewer infections compared to bacteria, the main limitation in drug development is not the frequency of infections. Even common infections like candidiasis or malaria require treatment, so infection prevalence alone does not explain the scarcity of effective drugs.

B. have fewer target sites compared to bacteria: These organisms do possess cellular structures that could be targeted, such as cell membranes, enzymes, or nucleic acids. The issue is not the number of potential targets but the similarity of those targets to human cells, which complicates drug design.

C. are so similar to human cells that selective drug toxicity is difficult to achieve: Fungi, protozoa, and helminths are eukaryotic, like human cells, meaning their cellular structures and metabolic pathways closely resemble those of the host. This similarity makes it challenging to develop drugs that are toxic to the pathogen but safe for human cells, limiting the number of available therapeutic options.

D. are parasites found inside human cells: While intracellular parasites pose delivery challenges for drugs, this is not the primary reason for the overall scarcity of antifungal, antiprotozoan, and antihelminth medications. Drug development is limited mainly by eukaryotic similarity rather than intracellular location alone.

E. are not affected by antimicrobics: This is incorrect because antifungal, antiprotozoan, and antihelminth drugs do exist and can be effective. The challenge is creating agents that selectively target these organisms without harming human cells, not an inherent resistance to all antimicrobial agents.